Evidence map›Paper›PMID 26949298›Full record

ArticleEthiopian journal of health sciences2015

How Effective is the Treatment of Locally Advanced and Metastatic Breast Cancer in Developing Centres?: A Retrospective Review.

Agodirin Olayide, Olatoke Samuel, Rahman Ganiyu, Adeoti Moses, Oyeyemi Gafar, Durojaiye Abiola, Kolawole Dapo, Agboola John

Open access · diamondAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Ethiopian journal of health sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Agodirin OlayideDepartment of Surgery, University of Ilorin and University of Ilorin Teaching Hospital, Kwara State, Nigeria.
Olatoke SamuelDepartment of Surgery, University of Ilorin and University of Ilorin Teaching Hospital, Kwara State, Nigeria.
Rahman GaniyuDepartment of Surgery, University of Ilorin and University of Ilorin Teaching Hospital, Kwara State, Nigeria.
Adeoti MosesDepartment of Surgery, Ladoke Akintola University of Technology and Ladoke Akintola Univeristy of Technology Teaching Hospital Ogbomoso, Oyo State, Nigeria.
Oyeyemi GafarDepartment of Statistics, Unversity of Ilorin, Kwara State, Nigeria.
Durojaiye AbiolaPain and Palliative Unit. University of Ilorin Teaching Hospital, Ilorin, Kwara, Nigeria.
Kolawole DapoDepartment of Surgery, Ladoke Akintola University of Technology and Ladoke Akintola Univeristy of Technology Teaching Hospital Ogbomoso, Oyo State, Nigeria.
Agboola JohnEkiti State University, Ekiti State, Nigeria.
University of Ilorin Teaching Hospital · NGLadoke Akintola University of Technology · NGEkiti State University · NGUniversity of Ilorin · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of chemotherapy in advanced metastatic breast cancer remains a subject of controversy. The thought of MicKinnon et al (early 1950s) that the course of breast cancer was unaffected by chemotherapy has been refuted by results of treatment in the developed countries. The poor result of treatment in developing centres still compares with prechemotherapy era. Consequently, The McKinnon's thought may still lurk. We compared the survival of chemotherapy treated with chemotherapy untreated cancer of breast patients.

methodRecords of breast cancer patients who presented and died between January 2010 and May 2014 were reviewed. The primary outcome was overall survival. Records of patients that received chemotherapy with or without other tumor directed specific therapy were compared with records of patients who did not receive any tumor directed therapy.

resultThirty-one patients received chemotherapy while 25 patients did not. All were females, more than 90% were of the patients had advanced or metastatic disease. Treatments were not biologically directed and treatment plans were largely compromised and suboptimal. The overall mean survival was 19.2 ±9.2 months, and the median duration was 17.5 months(range 6-44months). The overall survival was not statistically different between the two groups (p= 0.230, unequal variance assumed). The objective of using neoadjuvant chemotherapy for fungating lesions was not achieved.

conclusionIn advanced and metastatic breast cancer, outcomes of patients who receive suboptimal regimen of cytotoxic chemotherapy do not differ from chemotherapy untreated patients.

Indexed as

Developing CountriesOutcome and Process Assessment, Health CareAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsFemaleHumansMiddle AgedNeoadjuvant TherapyRetrospective StudiesSeverity of Illness IndexAntineoplastic Agentsbreast cancerchemotherapysuboptimal treatmentuntreated

Identifiers

PMID26949298
PMCPMC4762972
OpenAlexW1891972042

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.